Precision BioSciences Data Suggests Potential HBV Cure in Early Trial
Event summary
- Precision BioSciences will present Phase 1 ELIMINATE-B trial data at EASL Congress 2026 (Barcelona, May 27-30).
- The presentation (LB26-51656, LBP-043) focuses on biopsy data showing elimination and inactivation of cccDNA in Hepatitis B patients.
- PBGENE-HBV is designed to eliminate cccDNA, the root cause of chronic Hepatitis B, and inactivate integrated HBV DNA.
- The FDA has granted PBGENE-HBV Fast Track designation and indicated sustained loss of HBV DNA as an approvable endpoint.
The big picture
Precision BioSciences' PBGENE-HBV represents a novel approach to treating chronic Hepatitis B, a global health challenge affecting hundreds of millions. While existing therapies manage the disease, a curative treatment remains elusive. The company's ARCUS platform, and specifically PBGENE-HBV's focus on cccDNA elimination, positions it uniquely within the gene editing space, but success hinges on demonstrating robust efficacy and navigating the complexities of regulatory approval for a gene editing therapy.
What we're watching
- Clinical Efficacy
- The presentation's data will be scrutinized for the degree and durability of cccDNA elimination, as this is the core value proposition of PBGENE-HBV and a key indicator of potential curative impact.
- Regulatory Pathway
- The FDA’s stated endpoint of sustained HBV DNA loss will likely influence the trial design and regulatory strategy, and future data releases will be assessed against this benchmark.
- Competitive Landscape
- Given PBGENE-HBV's claim as the only gene editing program targeting cccDNA elimination, the emergence of competing approaches will be a key factor in its long-term commercial viability.
Related topics